Genmab rises on better-than-expected Q4, guidance

Genmab A/S

13/02/2025 08:49

** Shares in Genmab  GMAB.CO  rise 4.6% after the Danish
drugmaker reported its Q4 operating income and guidance above
expectations
    ** J.P.Morgan highlights EBIT and EBIT guidance beats as
"small positives", the beats coming as a result of lower R&D
spending
    ** JPM also points to Q4 revenues 1% ahead of company
consensus which was driven by a higher-than-expected cancer drug
Darzalex royalty rate of 19%
    ** Van Lanschot Kempen adds that the continued Darzalex
sales growth can provide a "robust" royalty stream for the
coming years
    ** Both JPM and Kempen note that the HexaBody-CD38 programme
weighs on the stock price and see Johnson & Johnson's  JNJ.N 
decision in Q1 2025 as potentially unburdening the shares
    ** The shares are on track for their best day in 2 months,
if the gains hold

 (Reporting by Vera Dvorakova)
 ((vera.dvorakova@thomsonreuters.com))